Education
About Us
Working with TipRanks
Follow Us
Atricure (ATRC)
NASDAQ:ATRC
ATRC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$26.92 - $43.11
Previous CloseN/A
Volume180.64K
Average Volume (3M)392.01K
Market Cap
$1.74B
Enterprise Value$1.52B
Total Cash (Recent Filing)$117.80M
Total Debt (Recent Filing)$77.25M
Price to Earnings (P/E)―
Beta1.15
Next Earnings
Oct 29, 2025EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding49,701,416
10 Day Avg. Volume292,014
30 Day Avg. Volume392,015
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue3.05
Enterprise Value/Gross Profit4.08
Enterprise Value/Ebitda-100.33
Forecast
1Y Price Target
$49.50Price Target Upside35.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Bulls Say, Bears Say
Bulls Say
Financial PerformanceATRC's revenue, EBITDA, and EPS exceeded consensus expectations.
GuidanceATRC raised its revenue, adjusted EBITDA, and EPS guidance for 2025.
Product LaunchesManagement noted that the product launches of both CryoSphere MAX and Flex-Mini are lifting the overall company growth rates.
Bears Say
Market Segment ChallengesThe company is seeing strong growth in the open segment and a decline in MIS due to PFA pressure.
Revenue PressureManagement effectively derisked MIS ablation revenue by guiding to sequential declines in category revenue as PFA continues to put pressure on this business.
Atricure News
ATRC FAQ
What was Atricure’s price range in the past 12 months?
Atricure lowest stock price was $26.92 and its highest was $43.11 in the past 12 months.
What is Atricure’s market cap?
Atricure’s market cap is $1.74B.
When is Atricure’s upcoming earnings report date?
Atricure’s upcoming earnings report date is Oct 29, 2025 which is in 18 days.
How were Atricure’s earnings last quarter?
Atricure released its earnings results on Jul 29, 2025. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.167 by $0.037.
Is Atricure overvalued?
According to Wall Street analysts Atricure’s price is currently Undervalued.
Does Atricure pay dividends?
Atricure does not currently pay dividends.
What is Atricure’s EPS estimate?
Atricure’s EPS estimate is -0.11.
How many shares outstanding does Atricure have?
Atricure has 49,701,416 shares outstanding.
What happened to Atricure’s price movement after its last earnings report?
Atricure reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.167. Following the earnings report the stock price went up 10.715%.
Which hedge fund is a major shareholder of Atricure?
Currently, no hedge funds are holding shares in ATRC
Atricure Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$49.50 (35.73% Upside)
$49.50 (35.73% Upside)
Blogger Sentiment
Bullish
ATRC Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 28.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $655.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 7.4%
Last 30 Days ▼ 7.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
34.97%
12-Months-Change
Fundamentals
Return on Equity
-7.85%
Trailing 12-Months
Asset Growth
1.94%
Trailing 12-Months
Company Description
Atricure
AtriCure, Inc. is a medical device company specializing in innovative solutions for the treatment of atrial fibrillation (AF) and other cardiac arrhythmias. Founded in 2000 and headquartered in Mason, Ohio, AtriCure develops and manufactures a range of products specifically designed to improve patient outcomes in heart surgery. Its core offerings include energy-based devices for cardiac ablation procedures, as well as accessories and surgical tools that enhance the effectiveness of these interventions. AtriCure operates primarily within the cardiology and surgical sectors, focusing on advancing minimally invasive techniques.
ATRC Company Deck
ATRC Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong performance by AtriCure, with significant revenue growth, increased profitability, and successful product launches. However, challenges remain in the hybrid therapy procedures segment due to competitive pressures. Overall, the positive aspects of the call, such as innovative product launches and international expansion, outweigh the negative aspects.View all ATRC earnings summariesATRC Stock 12 Month Forecast
Average Price Target
$49.50
▲(35.73% Upside)
Technical Analysis
Ownership Overview
3.54% Insiders
41.63% Mutual Funds
23.89% Other Institutional Investors
15.03% Public Companies and
Individual Investors